173 related articles for article (PubMed ID: 35582958)
1. Free vitamin D
Grut V; Biström M; Salzer J; Stridh P; Lindam A; Alonso-Magdalena L; Andersen O; Jons D; Gunnarsson M; Vrethem M; Hultdin J; Sundström P
Eur J Neurol; 2022 Aug; 29(8):2335-2342. PubMed ID: 35582958
[TBL] [Abstract][Full Text] [Related]
2. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study.
Weinstein SJ; Stolzenberg-Solomon RZ; Kopp W; Rager H; Virtamo J; Albanes D
Cancer Res; 2012 Mar; 72(5):1190-8. PubMed ID: 22232734
[TBL] [Abstract][Full Text] [Related]
3. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer.
Anic GM; Weinstein SJ; Mondul AM; Männistö S; Albanes D
PLoS One; 2014; 9(7):e102966. PubMed ID: 25036524
[TBL] [Abstract][Full Text] [Related]
4. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer.
Weinstein SJ; Mondul AM; Kopp W; Rager H; Virtamo J; Albanes D
Int J Cancer; 2013 Jun; 132(12):2940-7. PubMed ID: 23180681
[TBL] [Abstract][Full Text] [Related]
5. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' Health Study II.
Wang J; Eliassen AH; Spiegelman D; Willett WC; Hankinson SE
Cancer Causes Control; 2014 Jul; 25(7):819-27. PubMed ID: 24748579
[TBL] [Abstract][Full Text] [Related]
6. The plasma free fraction of 25-hydroxyvitamin D
Best CM; Thummel KE; Hsu S; Lin Y; Zelnick LR; Kestenbaum B; Kushnir MM; de Boer IH; Hoofnagle AN
J Steroid Biochem Mol Biol; 2023 Feb; 226():106206. PubMed ID: 36404469
[TBL] [Abstract][Full Text] [Related]
7. Binding properties of plasma vitamin D-binding protein and intestinal 1,25-dihydroxyvitamin D3 receptor in piglets with pseudo-vitamin D-deficiency rickets, type I: treatment effects with pharmacological doses of vitamin D3.
Kaune R; Schroeder B; Harmeyer J
Arch Biochem Biophys; 1990 Nov; 282(2):326-32. PubMed ID: 2173481
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma.
Mondul AM; Weinstein SJ; Moy KA; Männistö S; Albanes D
Int J Cancer; 2014 Jun; 134(11):2699-706. PubMed ID: 24214881
[TBL] [Abstract][Full Text] [Related]
9. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Weinstein SJ; Purdue MP; Smith-Warner SA; Mondul AM; Black A; Ahn J; Huang WY; Horst RL; Kopp W; Rager H; Ziegler RG; Albanes D
Int J Cancer; 2015 Mar; 136(6):E654-64. PubMed ID: 25156182
[TBL] [Abstract][Full Text] [Related]
10. Association of thyroid cancer risk with plasma 25-hydroxyvitamin D and vitamin D binding protein: a case-control study in China.
Hu MJ; Niu QS; Wu HB; Lu XL; Wang L; Tong XR; Huang F
J Endocrinol Invest; 2020 Jun; 43(6):799-808. PubMed ID: 31863361
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D-binding protein controls T cell responses to vitamin D.
Kongsbak M; von Essen MR; Levring TB; Schjerling P; Woetmann A; Ødum N; Bonefeld CM; Geisler C
BMC Immunol; 2014 Sep; 15():35. PubMed ID: 25230725
[TBL] [Abstract][Full Text] [Related]
12. 25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype.
Jones KS; Assar S; Harnpanich D; Bouillon R; Lambrechts D; Prentice A; Schoenmakers I
J Clin Endocrinol Metab; 2014 Sep; 99(9):3373-81. PubMed ID: 24885631
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Vitamin D Metabolism in Patients with Cushing's Disease in Response to 150,000 IU Cholecalciferol Treatment.
Povaliaeva A; Bogdanov V; Pigarova E; Zhukov A; Dzeranova L; Belaya Z; Rozhinskaya L; Mel'nichenko G; Mokrysheva N
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959880
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.
Hektoen HH; Robsahm TE; Stenehjem JS; Axcrona K; Babigumira R; Mondul AM; Gislefoss RE; Andreassen BK
Cancer Med; 2021 Jun; 10(12):4107-4116. PubMed ID: 34080787
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D-binding protein and pancreatic cancer: a nested case-control study.
Piper MR; Freedman DM; Robien K; Kopp W; Rager H; Horst RL; Stolzenberg-Solomon RZ
Am J Clin Nutr; 2015 Jun; 101(6):1206-15. PubMed ID: 25904602
[TBL] [Abstract][Full Text] [Related]
16. Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis.
Behrens JR; Rasche L; Gieß RM; Pfuhl C; Wakonig K; Freitag E; Deuschle K; Bellmann-Strobl J; Paul F; Ruprecht K; Dörr J
Eur J Neurol; 2016 Jan; 23(1):62-7. PubMed ID: 26220765
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis.
Simon KC; Munger KL; Xing Yang ; Ascherio A
Mult Scler; 2010 Feb; 16(2):133-8. PubMed ID: 20007432
[TBL] [Abstract][Full Text] [Related]
18. Bioavailable and free 25-hydroxyvitamin D and vitamin D binding protein in polycystic ovary syndrome: Relationships with obesity and insulin resistance.
Naderpoor N; Shorakae S; Abell SK; Mousa A; Joham AE; Moran LJ; Stepto NK; Spritzer PM; Teede HJ; de Courten B
J Steroid Biochem Mol Biol; 2018 Mar; 177():209-215. PubMed ID: 28734987
[TBL] [Abstract][Full Text] [Related]
19. Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis.
Smolders J; Peelen E; Thewissen M; Menheere P; Damoiseaux J; Hupperts R
Mult Scler; 2014 Apr; 20(4):433-7. PubMed ID: 23959712
[TBL] [Abstract][Full Text] [Related]
20. Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D.
Sollid ST; Hutchinson MY; Berg V; Fuskevåg OM; Figenschau Y; Thorsby PM; Jorde R
Eur J Endocrinol; 2016 Apr; 174(4):445-52. PubMed ID: 26733479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
